Glaukos Corporation Analysts Set Consensus Price Target at $116.92

Glaukos Corporation (NYSE:GKOS) has garnered a consensus recommendation of “Moderate Buy” from analysts, according to a report by MarketBeat Ratings. This assessment comes from a total of sixteen analysts currently covering the company. The ratings vary, with two analysts issuing a sell rating, two giving a hold rating, eleven rating it as a buy, and one analyst declaring a strong buy.

The average price objective for Glaukos shares over the next year has been established at approximately $116.92. Several analysts have recently provided insights on the company’s stock performance. On October 8, 2023, Weiss Ratings reaffirmed a “sell (d-)” rating for Glaukos. In a report published on October 7, Citigroup reduced its target price from $140.00 to $110.00, while maintaining a buy rating.

UBS Group also adjusted its target price on July 31, increasing it from $125.00 to $134.00, continuing to endorse Glaukos with a buy rating. William Blair upgraded the stock to a “strong buy” on the same day. Additionally, Wells Fargo & Company raised its target price from $86.00 to $92.00 while assigning an “equal weight” rating.

Stock Performance and Financial Insights

On October 10, 2023, Glaukos shares opened at $75.29. The company’s financial ratios indicate a quick ratio of 4.69, a current ratio of 5.51, and a debt-to-equity ratio of 0.09. Over the past twelve months, the stock has fluctuated between a low of $73.73 and a high of $163.71. As of now, the 50-day moving average stands at $86.71, while the 200-day moving average is at $91.88. Glaukos holds a market capitalization of $4.32 billion and a price-to-earnings ratio of -45.63.

On July 30, 2023, Glaukos reported its latest earnings results, revealing a loss of $0.24 per share, which exceeded analysts’ expectations of a loss of $0.26 per share by $0.02. The company reported revenue of $124.12 million for the quarter, surpassing analyst estimates of $115.49 million. This reflects a substantial year-over-year revenue growth of 29.7%, compared to a loss of $0.52 per share during the same period the previous year. For fiscal year 2025, Glaukos has set guidance at EPS, while analysts forecast a loss of $1.08 per share for the current fiscal year.

About Glaukos Corporation

Glaukos Corporation specializes in ophthalmic pharmaceuticals and medical technology, focusing on innovative therapies for conditions such as glaucoma, corneal disorders, and retinal diseases. The company offers products like the iStent and iStent inject W micro-bypass stents, which facilitate aqueous humor outflow during cataract surgery to treat mild-to-moderate open-angle glaucoma.

As the company continues to navigate the complexities of the healthcare market, analysts’ insights will play a pivotal role in shaping investor sentiment and guiding strategic decisions.